NLRP1 activation is of particular interest in that recent studies suggest that it is held in an inactive state by the serine dipeptidyl peptidases (DPP)8 and 9 and that inhibitors of these dipeptidases result in activation of NLRP1.(Zhong et al., 2018) Preclinical studies with non‐specific inhibitors of DPP8/9 (also known as PT100 or talabostat) had previously shown that these inhibitors had anti‐tumor effects that appeared mainly related to effects on the immune system(Adams et al., 2004). Here, DPP8 is linked to neoplasm.